Abstract 1898P
Background
Over the last decade there has been increased number of adolescent and young adults undergoing cancer-related treatments due to increased number of cancer diagnosis. For cancer patients, VR has been shown to be more effective than other forms of distraction for relieving anxiety, depression, and fatigue during chemotherapy. There is also a great variation of VR environments described in the literature from game playing to relaxing environment settings in nature.
Methods
The review was performed according PRISMA guideliness using search terms related to digital health, virtual reality, neoplasm, cancer, adolescent, young adults, treatment, oncology, home care, virtual environments to identify studies indexed in: MEDLINE(Ovid), PubMed, PsycInfo, Scopus, EMBASE, CINAHL in English language published from 2012-2022., in cancer patients aged 18 - 25 years old.
Results
The search yielded 823 initial records, including randomized controlled and case-controlled trials. For cancer patients, VR has been shown to be more effective than other forms of distraction for relieving anxiety, depression, and fatigue during chemotherapy. There is also a great variation of VR environments described in the literature from game playing to relaxing environment settings in nature. However there is not sufficient literature describing evidence in home-based settings of cancer patients receiving chemotherapy or any other oncology active treatments. Patients using HADS-D on average, had a 15% decrease in depression, 13% decrease in general anxiety after receiving the VR intervention. Their perception of pain decreased by 18%. Results were supported by the objective measures.
Conclusions
The availability of affordable commercial VR hardware has paralleled a growing interest in the use of the technology in the health sector. In the context of cancer care, there is a small but growing body of research into the use of VR technology. Findings hold significant potential for improving the support and care of cancer patients in remote settings. Key insights contribute to the advancement of patient-centered care strategies, fostering innovation in telemedicine and enhancing delivery of supportive services to individuals facing cancer diagnoses.
Clinical trial identification
379260.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1717TiP - CARE1 pragmatic clinical trial: First line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma
Presenter: Laurence Albiges
Session: Poster session 12
1822P - Incidence of cachexia and health resource use (HRU) in patients with breast, colorectal, lung, pancreatic, and prostate cancers
Presenter: Imran Ali
Session: Poster session 12
1823P - Significance of skeletal muscle measurement in cancer-associated cachexia screening
Presenter: Lynn Gottmann
Session: Poster session 12
1824P - Sarcopenia in advanced non-small cell lung cancer (NSCLC): Clinical impact and its biological correlates
Presenter: Filippo Dall'Olio
Session: Poster session 12
1826P - Risk factors and incidence of osteoporosis in patients with breast cancer according to gender
Presenter: Chang Ik Yoon
Session: Poster session 12
1827P - Bone health and body composition in prostate cancer: An italian consensus about prevention and management strategies
Presenter: Maria Concetta Cursano
Session: Poster session 12
1828P - A cross-sectional study investigating the current diagnostic & therapeutical approaches to bone metastases (BoM) in patients (pts) with non-small cell lung cancer (NSCLC)
Presenter: Sara Pilotto
Session: Poster session 12
1829P - Nutritional status assessment for patients with common cancer in a cancer hospital of southwest China
Presenter: Huiqing Yu
Session: Poster session 12
Resources:
Abstract
1830P - Comprehensive prognostic effects of inflammatory and nutritional markers to predict survival in women with breast cancer
Presenter: Susanna Hutajulu
Session: Poster session 12
1831P - Obesity and weight variations before treatment, seem to influence weight loss that happens during first-line metastatic lung adenocarcinoma
Presenter: Anthony Tarabay
Session: Poster session 12